Bronchitis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Hanlim Pharm, Ahn-Gook Pharma, Johnson & Johnson, PharmaKing, Yuhan Crp., Pfizer, Sanofi

Posted on
by

Bronchitis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Hanlim Pharm, Ahn-Gook Pharma, Johnson & Johnson, PharmaKing, Yuhan Crp., Pfizer, Sanofi
“Bronchitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchitis, historical and forecasted epidemiology as well as the Bronchitis market trends in the 7MM.

DelveInsight’s “Bronchitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchitis, historical and forecasted epidemiology as well as the Bronchitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Bronchitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchitis Market Forecast

 

Some of the key facts of the Bronchitis Market Report: 

  • The Bronchitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In February 2022, Zydus, a division of Cadila Healthcare, announced that its U.S. subsidiary obtained the final approval from the US Food and Drug Administration (FDA) to commercialize roflumilast tablets in a strength of 500 mcg. Additionally, tentative approval was granted for roflumilast tablets. These tablets are designated for reducing the likelihood of chronic obstructive pulmonary disease (COPD) exacerbations in patients experiencing severe COPD associated with chronic bronchitis and a history of exacerbations.
  • In 2022, the combined number of acute bronchitis cases in children and adults was estimated to be around 19,517,000 and approximately 29,174,000 cases, respectively, across the seven major markets (7MM). It is projected that these figures will rise during the forecast period.
  • In 2022, the overall instances of acute bronchitis among children and adults were approximately 1,574,000 and roughly 2,819,000 cases, respectively, specifically within Germany. It is expected that these numbers will rise during the forecast period.
  • In 2022, the collective instances of chronic bronchitis reached an estimated ~26,954,000 cases across the seven major markets (7MM). Projections indicate an expected increase in these cases by the year 2032.
  • France had the highest number of acute bronchitis cases among the EU4 countries and the UK. These cases accounted for approximately 47% of the total instances of acute bronchitis in the EU4 and the UK in 2022.
  • Key Bronchitis Companies: Hanlim Pharm. Co., Ltd., Ahn-Gook Pharmaceutical, Johnson & Johnson, PharmaKing, Yuhan Corporation, Pfizer, Korea United Pharma, Hyundai Pharma, Vitaccess Ltd, Bayer, Sanofi, and others
  • Key Bronchitis Therapies: HL301(Experimental), Bronpass Tab, AGS (Experimental), levofloxacin, N02RS1 1200mg, YHD001, Azithromycin SR, KALOMIN™ Tab., Acebrophylline, Guafenesin tablets, Avelox (Moxifloxacin, BAY12-8039), Telithromycin, and others
  • The Bronchitis epidemiology based on gender analyzed that in most of the countries, male predominance Bronchitis was observed
  • The Bronchitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchitis pipeline products will significantly revolutionize the Bronchitis market dynamics.

 

Bronchitis Overview

Bronchitis is an inflammatory condition that affects the air passages in the lungs, specifically the bronchial tubes, causing them to become swollen and irritated. This inflammation leads to a persistent cough and increased production of mucus.

 

Get a Free sample for the Bronchitis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/bronchitis-market

 

Bronchitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Bronchitis Epidemiology Segmentation:

The Bronchitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Bronchitis
  • Prevalent Cases of Bronchitis by severity
  • Gender-specific Prevalence of Bronchitis
  • Diagnosed Cases of Episodic and Chronic Bronchitis

 

Download the report to understand which factors are driving Bronchitis epidemiology trends @ Bronchitis Epidemiology Forecast

 

Bronchitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchitis market or expected to get launched during the study period. The analysis covers Bronchitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bronchitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Bronchitis Therapies and Key Companies

  • HL301(Experimental): Hanlim Pharm. Co., Ltd.
  • Bronpass Tab.: Hanlim Pharm. Co., Ltd.
  • AGS (Experimental): Ahn-Gook Pharmaceutical
  • levofloxacin: Johnson & Johnson
  • N02RS1 1200mg: PharmaKing
  • YHD001: Yuhan Corporation
  • Azithromycin SR: Pfizer
  • KALOMIN™ Tab.: Korea United Pharma
  • Acebrophylline: Hyundai Pharma
  • Guafenesin tablets: Vitaccess Ltd
  • Avelox (Moxifloxacin, BAY12-8039): Bayer
  • Telithromycin: Sanofi

 

Discover more about therapies set to grab major Bronchitis market share @ Bronchitis Treatment Landscape

 

Scope of the Bronchitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Bronchitis Companies: Hanlim Pharm. Co., Ltd., Ahn-Gook Pharmaceutical, Johnson & Johnson, PharmaKing, Yuhan Corporation, Pfizer, Korea United Pharma, Hyundai Pharma, Vitaccess Ltd, Bayer, Sanofi, and others
  • Key Bronchitis Therapies: HL301(Experimental), Bronpass Tab, AGS (Experimental), levofloxacin, N02RS1 1200mg, YHD001, Azithromycin SR, KALOMIN™ Tab., Acebrophylline, Guafenesin tablets, Avelox (Moxifloxacin, BAY12-8039), Telithromycin, and others
  • Bronchitis Therapeutic Assessment: Bronchitis current marketed and Bronchitis emerging therapies
  • Bronchitis Market Dynamics: Bronchitis market drivers and Bronchitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Bronchitis Unmet Needs, KOL’s views, Analyst’s views, Bronchitis Market Access and Reimbursement 

 

To know more about Bronchitis companies working in the treatment market, visit @ Bronchitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Bronchitis Market Report Introduction

2. Executive Summary for Bronchitis

3. SWOT analysis of Bronchitis

4. Bronchitis Patient Share (%) Overview at a Glance

5. Bronchitis Market Overview at a Glance

6. Bronchitis Disease Background and Overview

7. Bronchitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Bronchitis 

9. Bronchitis Current Treatment and Medical Practices

10. Bronchitis Unmet Needs

11. Bronchitis Emerging Therapies

12. Bronchitis Market Outlook

13. Country-Wise Bronchitis Market Analysis (2019–2032)

14. Bronchitis Market Access and Reimbursement of Therapies

15. Bronchitis Market Drivers

16. Bronchitis Market Barriers

17.  Bronchitis Appendix

18. Bronchitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/